Research News

TAS-102 prolongs overall survival in refractory colorectal cancer, study shows

BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h2620 (Published 15 May 2015) Cite this as: BMJ 2015;350:h2620
  1. Susan Mayor
  1. 1London

TAS-102, an oral drug that combines two agents to maintain blood levels of the active antitumour component, significantly prolongs survival in patients with metastatic colorectal cancer that is refractory to standard therapies, a phase III trial reported in the New England Journal of Medicine has shown.

Patients with colorectal cancer are routinely treated with fluoropyrimidines, which inhibit a key step …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe